A Glycosylated Prodrug to Attenuate Neuroinflammation and Improve Cognitive Deficits in Alzheimer's Disease Transgenic Mice

Citations

WEB OF SCIENCE

10
Citations

SCOPUS

11

초록

We report a prodrug, Glu-DAPPD, to overcome the shortcomings of an anti-neuroinflammatory molecule, N,N'-diacetyl-p-phenylenediamine (DAPPD), in biological applicability for potential therapeutic applications. We suspect that Glu-DAPPD can release DAPPD through endogenous enzymatic bioconversion. Consequently, Glu-DAPPD exhibits in vivo efficacies in alleviating neuroinflammation, reducing amyloid-beta aggregate accumulation, and improving cognitive function in Alzheimer's disease transgenic mice. Our studies demonstrate that the prodrug approach is suitable and effective toward developing drug candidates against neurodegeneration.

키워드

Alzheimer's disease; prodrug; anti-neuroinflammation; microglial function; amyloid-beta; ARYLAMINE N-ACETYLTRANSFERASES; MESENCHYMAL STEM-CELLS; MICROGLIAL DYSFUNCTION; BETA-GLUCOSIDASES; SPECIFICITY; TARGET; METABOLISM; CLEARANCE; MECHANISM; PROTEIN
제목
A Glycosylated Prodrug to Attenuate Neuroinflammation and Improve Cognitive Deficits in Alzheimer's Disease Transgenic Mice
저자
Kim, Mingeun; Park, Min Hee; Nam, Geewoo; Lee, Misun; Kang, Juhye; Song, Im-Sook; Choi, Min-Koo; Jin, Hee Kyung; Bae, Jae-Sung; Lim, Mi Hee
DOI
10.1021/acs.molpharmaceut.0c00677
발행일
2021-01-04
유형
Article
저널명
Molecular Pharmaceutics
권
18
호
1
페이지
101 ~ 112